Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • Lactate-Driven HMGB1 Release in Sepsis: Mechanisms and Impli

    2026-06-09

    Lactate-Driven HMGB1 Release in Sepsis: Mechanisms and Implications

    Study Background and Research Question

    Sepsis is a life-threatening syndrome characterized by excessive inflammation and organ dysfunction in response to infection. Elevated serum lactate and high mobility group box-1 protein (HMGB1) levels are both established markers of sepsis severity and mortality. However, despite these clinical correlations, the mechanistic link between lactate and HMGB1 release during sepsis has remained unclear. The reference study (Yang et al., 2022) addressed whether lactate directly modulates HMGB1 release from macrophages, thereby exacerbating systemic inflammation in polymicrobial sepsis.

    Key Innovation from the Reference Study

    The key innovation of this work is the demonstration that lactate is not merely a metabolic byproduct or prognostic biomarker in sepsis, but a causal mediator. Specifically, the study uncovers that macrophages exposed to elevated lactate undergo both lactylation and acetylation of HMGB1, post-translational modifications that facilitate HMGB1’s translocation and exosomal release. The research further elucidates the upstream signaling: lactate uptake by monocarboxylate transporters (MCTs), p300/CBP-dependent lactylation, GPR81-mediated signaling, and Hippo/YAP pathway involvement in acetylation. This mechanistic insight shifts the paradigm, positioning lactate and its associated signaling as promising targets for therapeutic intervention in sepsis.

    Methods and Experimental Design Insights

    The investigators employed both in vivo and in vitro models to dissect the role of lactate in HMGB1 regulation. Key approaches included:

    • Animal Models: Polymicrobial sepsis was induced in wild-type and genetically modified mice (including macrophage-specific YAP knockouts created via Cre/LoxP recombination) to interrogate pathway dependencies.
    • HMGB1 Detection: Serum and exosomal HMGB1 levels were quantified by ELISA and immunoblotting, correlating these with lactate concentrations.
    • Post-Translational Modification Analyses: Immunoprecipitation and mass spectrometry characterized HMGB1 lactylation and acetylation states in macrophages after lactate exposure.
    • Pharmacological and Genetic Interventions: Inhibition of lactate production, GPR81 receptor blockade, and YAP knockout were used to dissect signaling pathways.
    • Endothelial Cell Assays: The impact of exosome-associated HMGB1 on endothelial permeability was evaluated using transwell systems.

    This multifaceted design allowed the authors to map the entire pathway from extracellular lactate sensing to HMGB1 exosomal release and functional vascular consequences.

    Core Findings and Why They Matter

    The central findings of the study, supported by direct experimental evidence, are:

    • Lactate Uptake Drives HMGB1 Modifications: Macrophages internalize extracellular lactate via MCTs, which promotes p300/CBP-mediated lactylation of HMGB1. Concurrently, lactate enhances acetylation through GPR81 activation, β-arrestin2 recruitment, and Hippo/YAP pathway suppression of deacetylase SIRT1.
    • Facilitated Exosomal Release: These modifications target HMGB1 for exosomal packaging and secretion. Serum exosomes from septic mice contained elevated HMGB1, correlating with increased lactate levels (Yang et al., 2022).
    • Functional Endothelial Impact: Exosomal HMGB1 from macrophages significantly increased endothelial permeability, a key event in sepsis-induced vascular leakage and organ dysfunction.
    • Therapeutic Modulation: Pharmacological inhibition of lactate production or GPR81 signaling reduced exosomal HMGB1 release and improved survival outcomes in septic mice.

    These results collectively suggest that targeting lactate metabolism or its signaling axis can mitigate the maladaptive inflammatory cascade in sepsis, opening new avenues for therapeutic development.

    Protocol Parameters

    • Sepsis induction: Use cecal ligation and puncture (CLP) or polymicrobial challenge in wild-type or gene-targeted mice to model acute sepsis.
    • Lactate modulation: Apply pharmacological inhibitors of lactate production (e.g., oxamate) or employ GPR81 antagonists prior to or shortly after sepsis induction, based on study protocols.
    • HMGB1 analysis: Collect serum and isolate exosomes for HMGB1 quantification by ELISA or immunoblot. Use immunoprecipitation and mass spectrometry for post-translational modification assessment.
    • Endothelial permeability assays: Expose endothelial monolayers to exosome preparations to assess barrier function.
    • Genetic interventions: Cross YAPflox/flox mice with Lyz2-Cre lines to generate macrophage-specific knockouts for pathway analysis.

    Comparison with Existing Internal Articles

    The mechanistic insights from Yang et al. inform broader inflammation research, particularly regarding the modulation of cytokine release and inflammasome activation. Recent internal reviews, such as "Translating NLRP3 Inflammasome Inhibition: NBC19 as a Strategic Probe", have highlighted the importance of precise inhibitors for dissecting inflammasome pathways. NBC19, described as a nanomolar NLRP3 inflammasome inhibitor, is shown to suppress IL-1β release in THP1 cells and modulate both Nigericin- and ATP-induced inflammasome activation (see internal resource). While the reference study centers on HMGB1, the shared theme is the centrality of metabolic and post-translational regulation of inflammatory mediators. The ability to precisely inhibit inflammasome-driven cytokine release, as with NBC19, is highly relevant for experimental designs extending from the HMGB1 axis to broader NLRP3-driven inflammation research workflows.

    Limitations and Transferability

    Despite its comprehensive approach, the study has several limitations. Most findings derive from mouse models and in vitro macrophage systems, which, while robust, may not fully capture the complexity of human sepsis. The dependence on pharmacological inhibitors and gene knockouts introduces potential off-target or compensatory effects. Furthermore, the study focuses on acute polymicrobial sepsis, so transferability to other inflammatory or infectious contexts requires further investigation. Importantly, while the lactate-HMGB1 axis is compelling, interaction with other pattern recognition and inflammasome pathways (including NLRP3) deserves additional exploration in translational research.

    Research Support Resources

    For researchers aiming to interrogate inflammasome activation and cytokine release in sepsis or other models of inflammation, precise chemical probes are essential. NBC19 (SKU BA6129) from APExBIO is a potent small molecule NLRP3 inflammasome inhibitor, exhibiting an IC50 of 60 nM in differentiated THP1 cells and providing effective suppression of IL-1β release induced by Nigericin and ATP. Incorporating NBC19 into experimental workflows supports high-resolution dissection of NLRP3-dependent signaling and cytokine production, complementing mechanistic studies such as those elucidating lactate-driven HMGB1 release. For optimal performance, researchers should follow recommended storage and handling protocols for NBC19 to maintain compound activity during inflammation research.